Global Blood Tests for Alzheimer's Diagnosis Market Strategic Research Report

Scope of the Report

The global Blood Tests for Alzheimer's Diagnosis market size is predicted to grow from US$ 70.58 million in 2025 to US$ 128 million in 2032; it is expected to grow at a CAGR of 8.9% from 2026 to 2032.

Blood Tests for Alzheimer's Diagnosis refer to diagnostic or biomarker testing methods that analyze Alzheimer's disease-related biomarkers in peripheral blood samples. These tests are designed to support the assessment of amyloid pathology, tau abnormalities, neurodegeneration, and neuroinflammation associated with Alzheimer's disease. Compared with cerebrospinal fluid testing and PET imaging, blood-based tests are less invasive, easier to perform, more accessible, and relatively more cost-effective. They are mainly used for diagnostic support in patients with cognitive impairment, clinical triage, treatment eligibility assessment, disease monitoring, and subject screening in drug development and clinical trials. The average price for end-point testing services is approximately US$500–900 per test.

The upstream supply chain of Blood Tests for Alzheimer's Diagnosis mainly includes antibodies, recombinant proteins, calibrators, quality controls, magnetic beads, enzyme labels, chemiluminescent substrates, assay raw materials, sample preparation consumables, chemiluminescent platforms, single-molecule immunoassay platforms, mass spectrometry systems, and related algorithms and data analysis software. The midstream segment consists of blood-based diagnostic product and platform companies that develop assays, instruments, and multi-biomarker panels targeting markers such as pTau, Aβ, NfL, GFAP, and ApoE. The downstream segment includes neurology departments, memory clinics, independent clinical laboratories, specialty testing centers, pharmaceutical companies, CROs, universities, and research institutions, with applications covering clinical diagnostic support, patient stratification, treatment monitoring, clinical trial enrollment, and Alzheimer’s disease biomarker research.

The Blood Tests for Alzheimer's Diagnosis market is entering a critical transition phase from research validation to clinical commercialization. With growing clinical evidence for blood-based biomarkers such as pTau, Aβ, NfL, and GFAP, and increasing demand for patient screening and stratification driven by anti-amyloid therapies, blood tests are expected to become an important supporting tool in the Alzheimer’s disease diagnostic pathway. Compared with PET imaging and cerebrospinal fluid testing, blood-based tests offer clear advantages in convenience, accessibility, and cost efficiency, making them particularly suitable for clinical triage, treatment eligibility assessment, and broader patient pre-screening. Future market growth will be driven by improvements in test accuracy, regulatory progress, physician adoption, laboratory channel expansion, and rising demand from drug development. However, the market still faces challenges related to clinical guideline adoption, reimbursement, assay standardization, and comparability across different technology platforms.

Segmentation Commercialization Status:

This report presents a comprehensive overview of the global Blood Tests for Alzheimer's Diagnosis market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

• Single Biomarker Tests
• Multi-Biomarker Panel Tests
• Others

Segment by Application

• Clinical Use
• Non-Clinical Use

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Blood Tests for Alzheimer's Diagnosis market:

• Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
• Distributors, channel partners and end users in Clinical Use, Non-Clinical Use evaluating demand and sourcing options
• Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
• Government agencies, industry associations and research institutions tracking industry developments and policy impact